A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
Phase 1
Active, not recruiting
- Conditions
- Advanced Head and Neck Squamous Cell CarcinomaAdvanced Breast CancerAdvanced Melanoma
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Cytovation AS
- Target Recruit Count
- 90
- Registration Number
- NCT05383170
- Locations
- 🇳🇱
NKI/AvL, Amsterdam, Netherlands
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇳🇱Maastricht UMC, Maastricht, Netherlands
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
Phase 1
Completed
- Conditions
- Advanced Solid Tumor Malignancy
- Interventions
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Cytovation AS
- Target Recruit Count
- 60
- Registration Number
- NCT04260529
- Locations
- 🇪🇸
Vall d'Hebron (VHIO), Barcelona, Spain
🇳🇱NKI/AvL, Amsterdam, Netherlands
🇫🇷Institute Gustave Roussy, Villejuif, France
CyPep-1 in Cutaneous Warts
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Centre for Human Drug Research, Netherlands
- Target Recruit Count
- 56
- Registration Number
- NCT03846648
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Zuid-Holland, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath